Lazard Asset Management
KROS icon

Lazard Asset Management’s Keros Therapeutics KROS Stock Holding History

Lazard Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,705
Closed -$129K – 2053
2026
Q1 		$129K Buy
+11,705
New +$181K ﹤0.01% 1695
2025
Q3 		– Sell
-21,849
Closed -$291K – 2085
2025
Q2 		$291K Buy
+21,849
New +$295K ﹤0.01% 1626
2022
Q2 		– Sell
-1,237
Closed -$67K – 2475
2022
Q1 		$67K Buy
+1,237
New +$63.5K ﹤0.01% 1587

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Lazard Asset Management's KROS Position: Q2 2026 in Review

Lazard Asset Management sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 11,705 shares — an estimated $129K sold.

Lazard Asset Management first reported a position in KROS in Q1 2022 and held it in 3 quarters. The position peaked at $291K in Q2 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Lazard Asset Management reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 11,705 Keros Therapeutics shares in Q2 2026, an estimated $129K.
  • Lazard Asset Management first reported a position in Keros Therapeutics in Q1 2022 and held it in 3 quarters.
  • Lazard Asset Management's Keros Therapeutics position peaked at $291K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.